Global Health Partner utilizes existing share purchase warrants

NewsGuard 100/100 Score

Global Health Partner's (STO:GHP) CEO Per Båtelson and Deputy CEO Johan Wachtmeister have utilized existing share purchase warrants and acquired 527,444 and 527,445 shares, respectively, in Global Health Partner. The warrants were issued by a number of Global Health Partner’s shareholders, mainly by Metroland BVBA, and the strike price was 75 pence, corresponding to approximately SEK 8.75. After the transaction Per Båtelson’s shareholding (incl. the holdings of related parties) amounts to a total of 3,814,044 shares. For Johan Wachtmeister the corresponding figure amounts to 4,378,931 shares. The total number of shares in Global Health Partner amounts to 64,816,074. The percentage of shares owned by Per Båtelson thereby amounts to 5.9% and the percentage owned by Johan Wachtmeister to 6.8%.

Furthermore, Per Båtelson and Johan Wachtmeister have each issued 75,000 share purchase warrants in Global Health Partner at current market rates to the company’s Chief Operating Officer, Ann-Sofi Lodin. The term of the warrants is 3 years and the strike price is SEK 16.00 per share.

Posted in:

Tags: ,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds accounting for sex improves precision and prognostic performance of CMR biomarkers for heart failure